Dutasteride: Why don't some doctors prescribe it if it's stronger than finasteride?

Dutasteride is a drug known for its effectiveness in treating androgenic alopecia and benign prostatic hyperplasia. It works by inhibiting 5-alpha reductase, an enzyme that converts testosterone to dihydrotestosterone (DHT), the hormone responsible for hair loss. Even though dutasteride is more potent than finasteride in its ability to reduce DHT levels, not all doctors prescribe it. There are several reasons for this cautious approach.

Risk of More Serious Side Effects:

One of the main reasons why some doctors hesitate to prescribe dutasteride, despite its effectiveness, is the increased risk of side effects. Dutasteride, being more potent than finasteride, has a greater potential to cause adverse effects on the reproductive system and other body systems.

An FDA study on 5-alpha reductase inhibitors warns that the use of these drugs may increase the risk of serious sexual side effects, including erectile dysfunction, decreased sexual desire, and ejaculation disorders. Additionally, while finasteride can also cause these effects, dutasteride appears to be associated with a higher incidence of side effects due to its greater potency in inhibiting DHT.

A study published in the Journal of Clinical Endocrinology and Metabolism found that men taking dutasteride reported higher rates of persistent sexual dysfunction compared to those taking finasteride. As a result, doctors often prefer to prescribe finasteride first, especially if the patient has not experienced adverse effects with it.

Concerns About Long-Term Safety:

Although dutasteride is effective in treating alopecia and other conditions, studies on its long-term effects are still limited. While there is strong evidence demonstrating its ability to reduce DHT, the lack of long-term safety data has led some doctors to be cautious. Finasteride, although not without risks, has been used for a longer period and has a more established safety record. In addition, some users report persistent side effects even after stopping treatment, a phenomenon known as post-finasteride syndrome (PFS).

While PFS is more commonly associated with finasteride, similar concerns have been raised regarding dutasteride due to its stronger inhibition of DHT. This has raised concerns among physicians about its long-term impact on sexual function and psychological well-being.

Possible Link to Prostate Cancer and Effects on the Endocrine System

Another important consideration is the relationship between dutasteride and prostate cancer. While some studies suggest that dutasteride may reduce the risk of low-grade prostate cancer, others indicate that its use could be associated with an increased risk of developing high-grade prostate cancer. Furthermore, dutasteride affects the endocrine system more intensely because it inhibits both isoforms of 5-alpha reductase (types I and II). This could have broader hormonal effects on the body, which may be of particular concern for younger men or individuals with a history of hormonal imbalances.

Preference for Proven and Well-Studied Treatments

Finasteride, despite having potential side effects, has been used for a longer time and has more clinical studies supporting its efficacy and safety in treating androgenic alopecia. Physicians often prefer to prescribe it first because of its more established safety profile and the availability of long-term clinical data.

Conclusion

Although dutasteride is more potent and effective at reducing DHT than finasteride, physicians often take a cautious approach when prescribing it due to the increased risk of side effects, the lack of extensive long-term safety data, and concerns about its effects on the endocrine system and prostate cancer risk. Patients considering dutasteride should discuss these factors with their doctor to determine whether it is the right treatment option for them.

Amory, J. K., Wang, C., Swerdloff, R. S., Anawalt, B. D., Matsumoto, A. M., Bremner, W. J., & Clark, R. V. (2007). The effect of 5α-reductase inhibition with dutasteride and finasteride on semen parameters and serum hormones in healthy men. The Journal of Clinical Endocrinology & Metabolism, 92(5), 1659–1665. https://doi.org/10.1210/jc.2006-2064

U.S. Food and Drug Administration. (2011). FDA Drug Safety Communication: 5-alpha reductase inhibitors (5-ARIs) may increase risk of more serious side effects. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-5-alpha-reductase-inhibitors-5-aris-may-increase-risk-more-serious

Nickel, J. C., Fradet, Y., Boake, R. C., Pommerville, P. J., Perreault, J. P., Afridi, S. K., ... & Barkin, J. (2004). Efficacy and safety of finasteride therapy for androgenetic alopecia: A randomized controlled trial. Canadian Journal of Urology, 11(6), 2518–2525. https://pmc.ncbi.nlm.nih.gov/articles/PMC2684818/

Thompson, I. M., Goodman, P. J., Tangen, C. M., Lucia, M. S., Miller, G. J., Ford, L. G., ... & Coltman, C. A. (2003). The influence of finasteride on the development of prostate cancer. New England Journal of Medicine, 349(3), 215-224. https://doi.org/10.1056/NEJMoa030660